Skip to content

TG Therapeutics TGTX Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively

Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively at other companies

Biogen logo
BiogenBIIB
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
Arrowhead Research logo
Arrowhead ResearchARWR
Roivant Sciences logo
Roivant SciencesROIV

Other financials

Income statement

See full
Revenue$204.9M+69.6%
Gross profit$171.4M+62.8%
Operating income$34.8M+304%
Net income$19.8M+291%
EPS (diluted)$0.12+300%

Balance sheet

See full
Cash & equivalents$442.2M+235%
Total debt$753.6M+197%
Total equity$583.1M+146%
Total assets$1.5B+133%

Cash flow

See full
Operating cash flow-$17.9M+37.7%
CapEx$51.0K+104%
Free cash flow-$17.9M+37.6%

Valuation

See full
Market cap$8.15B-14.3%
Enterprise value$8.46B-11.1%
P/E17.6×-225×
P/S11.6×-13.0×

Profitability

See full
Gross margin83.1%-4.4pp
Operating margin21.3%+5.9pp
Net margin66%+55.8pp
FCF margin-6,328.4%+4,773pp

Returns & leverage

See full
Return on equity112.6%+92.9pp
Debt / equity1.3×+0.2×
Current ratio5.8×+1.8×

Where this comes from

Reported directly by TG Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about TG Therapeutics's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TG Therapeutics's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively?
TG Therapeutics (TGTX) reported common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively of $160K in Q1 2026.
How has TG Therapeutics's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively changed year-over-year?
TG Therapeutics's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively increased by 0.6% year-over-year, from $159K to $160K.
What is the long-term trend for TG Therapeutics's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively?
Over 5 years (2020 to 2025), TG Therapeutics's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively has grown at a 2.4% compound annual growth rate (CAGR), from $141K to $159K.